Complications of Computed Tomography-Guided High-Dose-Rate Brachytherapy (CT-HDRBT) and Risk Factors: Results from More than 10 Years of Experience
- 8 Downloads
For local ablation of unresectable tumors, computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT) is a minimally invasive therapeutic option involving CT-guided catheter placement and high-dose-rate irradiation with iridium-192. Possible complications are related to transcutaneous puncture, retraction of the applicator, and delivery of brachytherapy. To classify CT-HDRBT in comparison with other minimally invasive therapeutic options, it is essential to know the probability of complications and their risk factors. This study therefore aimed at quantifying the occurrence of complications in CT-HDRBT and identifying potential risk factors.
Materials and Methods
Over a period of more than 10 years from 2006 to 2017, 1877 consecutive CT-HDRBTs were performed at our center and retrospectively analyzed. In 165 cases, CT-HDRBT was combined with transarterial (chemo-) embolization. Information on complications and potential risk factors was retrospectively retrieved from electronic documentation. Statistical analysis of the data was performed.
No complications occurred in 85.6% of the interventions. The most common complications were bleeding (5.6%), infection (2.0%), and prolonged pain (1.5%). Summarized diameter (defined as sum of maximum diameters in axial orientation) of treated tumor lesions (odds ratio 1.008; p < 0.001), target lesion site (odds ratio 1.132; p = 0.033), combined treatment (odds ratio 1.233; p = 0.038), and the presence of biliodigestive anastomosis (BDA) (odds ratio 1.824; p = 0.025) were identified as risk factors.
CT-HDRBT is a safe minimally invasive therapeutic option. Summarized diameter of treated tumor lesions, target lesion site, combined treatment, and presence of BDA are risk factors for complications.
KeywordsBrachytherapy Therapeutics Risk factors Hemorrhage Infection
Computed tomography-guided high-dose-rate brachytherapy
Clinical target volume
Non-small cell lung cancer
Transarterial (chemo-) embolization
Society of Interventional Radiology
GB wrote the manuscript und supervised analysis. LB collected the data and performed analysis. MJ and WML supported data collection and analysis. TD, DS, GW, PW and BG performed the interventions. BG supervised study planning and supported manuscript writing. All authors read and approved the final manuscript.
The authors declare that they received no funding.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics Approval and Consent to Participate
This study been performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Charité (EA4/089/17).
Consent for Publication
Written informed consent for the publication was obtained from participants.
- 1.Collettini F, Singh A, Schnapauff D, Powerski MJ, Denecke T, Wust P, et al. Computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of metastases adjacent to the liver hilum. Eur J Radiol. 2013;82(10):e509–14. https://doi.org/10.1016/j.ejrad.2013.04.046.CrossRefPubMedGoogle Scholar
- 3.Collettini F, Schnapauff D, Poellinger A, Denecke T, Schott E, Berg T, et al. Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (> 7 cm) tumours. Eur Radiol. 2012;22(5):1101–9. https://doi.org/10.1007/s00330-011-2352-7.CrossRefPubMedGoogle Scholar
- 4.Denecke T, Stelter L, Schnapauff D, Steffen I, Sinn B, Schott E, et al. CT-guided interstitial brachytherapy of hepatocellular carcinoma before liver transplantation: an equivalent alternative to transarterial chemoembolization? Eur Radiol. 2015;25(9):2608–16. https://doi.org/10.1007/s00330-015-3660-0.CrossRefPubMedGoogle Scholar
- 5.Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys. 2010;78(1):172–9. https://doi.org/10.1016/j.ijrobp.2009.07.1700.CrossRefPubMedGoogle Scholar
- 6.Geisel D, Collettini F, Denecke T, Grieser C, Flörcken A, Wust P, et al. Treatment for liver metastasis from renal cell carcinoma with computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT): a case series. World J Urol. 2013;31(6):1525–30. https://doi.org/10.1007/s00345-012-0981-3.CrossRefPubMedGoogle Scholar
- 8.Wieners G, Mohnike K, Peters N, Bischoff J, Kleine-Tebbe A, Seidensticker R, et al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy—a phase II-study. Radiother Oncol. 2011;100(2):314–9. https://doi.org/10.1016/j.radonc.2011.03.005.CrossRefPubMedGoogle Scholar
- 9.Jonczyk M, Collettini F, Schnapauff D, Geisel D, Boning G, Feldhaus F, et al. Cholangiocarcinoma: CT-guided high-dose rate brachytherapy (CT-HDRBT) for limited (< 4 cm) and Large (> 4 cm) tumors. Anticancer Res. 2018;38(10):5843–52. https://doi.org/10.21873/anticanres.12926.CrossRefPubMedGoogle Scholar
- 10.Collettini F, Schnapauff D, Poellinger A, Denecke T, Banzer J, Golenia MJ, et al. Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates. Rofo. 2012;184(4):316–23. https://doi.org/10.1055/s-0031-1299101.CrossRefPubMedGoogle Scholar
- 11.Peters N, Wieners G, Pech M, Hengst S, Rühl R, Streitparth F, et al. CT-guided interstitial brachytherapy of primary and secondary lung malignancies: results of a prospective phase II trial. Strahlenther Onkol. 2008;184(6):296–301. https://doi.org/10.1007/s00066-008-1718-5.CrossRefPubMedGoogle Scholar
- 13.Jonczyk M, Collettini F, Schnapauff D, Geisel D, Boning G, Feldhaus F, et al. Primary and metastatic malignancies of the lung: retrospective analysis of the CT-guided high-dose rate brachytherapy (CT-HDRBT) ablation in tumours < 4 cm and ≥ 4 cm. Eur J Radiol. 2018;108:230–5. https://doi.org/10.1016/j.ejrad.2018.10.008.CrossRefPubMedGoogle Scholar
- 16.Schnapauff D, Denecke T, Grieser C, Collettini F, Colletini F, Seehofer D, et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Interv Radiol. 2012;35(3):581–7. https://doi.org/10.1007/s00270-011-0249-0.CrossRefGoogle Scholar
- 17.Mohnike K, Wolf S, Damm R, Seidensticker M, Seidensticker R, Fischbach F, et al. Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy: complications and risk factors. Strahlenther Onkol. 2016;192(5):288–96. https://doi.org/10.1007/s00066-016-0957-0.CrossRefPubMedGoogle Scholar
- 18.Tselis N, Ferentinos K, Kolotas C, Schirren J, Baltas D, Antonakakis A, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in the local treatment of primary and secondary intrathoracic malignancies. J Thorac Oncol. 2011;6(3):545–52. https://doi.org/10.1097/JTO.0b013e318208c7a3.CrossRefPubMedGoogle Scholar
- 26.Ricke J, Wust P, Wieners G, Beck A, Cho CH, Seidensticker M, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol. 2004;15(11):1279–86. https://doi.org/10.1097/01.RVI.0000141343.43441.06.CrossRefPubMedGoogle Scholar